500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
Phase I and Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, liver cirrhosis with ascites (LCWA) and syndrome of inappropriate antidiuretic hormone (SIADH). Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH) and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan resulted in correction in hyponatremia together with a marked aquaresis in subjects with volume overload. The present study is designed to confirm and extend the observations from previous studies that lixivaptan
therapy corrects hyponatremia, in euvolemic subjects, including subjects with SIADH.
To demonstrate that lixivaptan is safe and effective in achieving and maintaining increased serum sodium concentration in patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and other
conditions of euvolemic hyponatremia.
Sponsor: Cardikine Biopharma,LLC
Phase: Phase 3
Trial ID: CK-LX3405
Not Accepting Healthy Volunteers